Ex parte CLARK et al. - Page 2




              Appeal No.  2001-2308                                                                                            
              Application 07/704,578                                                                                           

              28. A pharmaceutical composition which comprises an effective amount of a polypeptide                            
              having the sequence:                                                                                             
              Ala Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala Ala Pro His Arg Gln Pro Leu Thr Ser                          
              Ser Glu Arg Ile Asp Lys Gln Ile Arg Tyr Ile Leu Asp Gly Ile Ser Ala Leu Arg Lys Glu Thr Cys Asn                  
              Lys Ser Asn MET Cys Glu Ser Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu Asn Leu Pro Lys                              
              MET Ala Glu Lys Asp Gly Cys Phe Gln Ser Gly Phe Asn Glu Glu Thr Cys Leu Val Lys Ile Ile Thr                      
              Gly Leu Leu Glu Phe Glu Val Tyr Leu Glu Tyr Leu Gln Asn Arg Phe Glu Ser Ser Glu Glu Gln Ala                      
              Arg Ala Val Gln MET Ser Thr Lys Val Leu Ile Gln Phe Leu Gln Lys Lys Ala Lys Asn Leu Asp                          
              Ala Ile Thr Thr Pro Asp Pro Thr Thr Asn Ala Ser Leu Leu Thr Lys Leu Gln Ala Gln Asn Gln Trp                      
              Leu Gln Asp MET Thr Thr His Leu Ile Leu Arg Ser Phe Lys Glu Phe Leu Gln Ser Ser Leu Arg                          
              Ala Leu Arg Gln MET                                                                                              
              in combination with a pharmaceutically acceptable vehicle, wherein said polypeptide is non-                      
              glycosylated.                                                                                                    
                      29. A bacterially produced non-glycosylated protein substantially free of other                          
              protein and characterized by the amino acid sequence:                                                            
              Ala Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala Ala Pro His Arg Gln Pro Leu Thr Ser                          
              Ser Glu Arg Ile Asp Lys Gln Ile Arg Tyr Ile Leu Asp Gly Ile Ser Ala Leu Arg Lys Glu Thr Cys Asn                  
              Lys Ser Asn MET Cys Glu Ser Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu Asn Leu Pro Lys                              
              MET Ala Glu Lys Asp Gly Cys Phe Gln Ser Gly Phe Asn Glu Glu Thr Cys Leu Val Lys Ile Ile Thr                      
              Gly Leu Leu Glu Phe Glu Val Tyr Leu Glu Tyr Leu Gln Asn Arg Phe Glu Ser Ser Glu Glu Gln Ala                      
              Arg Ala Val Gln MET Ser Thr Lys Val Leu Ile Gln Phe Leu Gln Lys Lys Ala Lys Asn Leu Asp                          
              Ala Ile Thr Thr Pro Asp Pro Thr Thr Asn Ala Ser Leu Leu Thr Lys Leu Gln Ala Gln Asn Gln Trp                      
              Leu Gln Asp MET Thr Thr His Leu Ile Leu Arg Ser Phe Lys Glu Phe Leu Gln Ser Ser Leu Arg                          
              Ala Leu Arg Gln MET                                                                                              
                      The examiner relies on the following references:                                                         
              Hirano et al (Hirano) “Purification to homogeneity and Characterization of Human B-Cell                          
              Differentiation Factor (BCDF or BSFp-2),” Proc.Natl Acad.Sci Vol. 82. pp. 5490-5494 (1985)                       
              Weissenbach et al (Weissenbach), “Two Interferon mRNAs in Human Fibroblasts: In Vitro                            
              Translation and Escherichia Coli Cloning Studies,”  Proc. Natl. Acad. Sci Vol. 77,                               
              pp. 7152-7156 (1980)                                                                                             



                                                              2                                                                





Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  Next 

Last modified: November 3, 2007